Membrane microvesicles: Macromessengers in cancer disease and progression
Membrane microvesicles: Macromessengers in cancer disease and progression
复制标题
DOI：
10.1016/s0049-3848(10)70021-9
复制
发表时间：
2010-04-01
影响因子：
7.5
通讯作者：
Freyssinet, Jean-Marie
中科院分区：
文献类型：
--
作者：
Castellana, Donatello;Toti, Florence;Freyssinet, Jean-Marie
血栓性并发症已在癌症患者中记录，并与肿瘤进展相关。癌症患者具有增加的循环亚微米（0.1-1 μ m）膜片段水平，所述亚微米膜片段被称为微泡（MV）或微粒。MV水平和表型的变化使其成为血栓性疾病和血管损伤的相关致病标志物。MV从活化或凋亡细胞的质膜释放，并且被认为是止血或血栓形成反应的有效效应物。它们的主要特征是在其表面存在促凝血磷脂，并且最终存在组织因子，这取决于它们来源的细胞。这些促凝血实体允许它们在血管内引发和传播血栓形成反应。MV也被认为是细胞间通讯的近端或远端介质。MV与靶细胞相互作用的机制仍不清楚，尽管许多研究表明MV-细胞融合和/或配体-受体相互作用。然而，必须强调的是，MV不一定引起有害反应。本文综述了MV在癌症相关血栓形成中的作用。(C)2010爱思唯尔有限公司版权所有。
Thrombotic complications have been documented in patients with cancer, and associated with tumor progression. Cancer patients have an increased level of circulating submicrometric (0.1-1 mu m) membrane fragments termed microvesicles (MV) or microparticles. Variations in MV levels and phenotypes make them relevant pathogenic markers of thrombotic disorders and vascular damage. MV are released from the plasma membrane of activated or apoptotic cells, and are considered efficient effectors of the hemostatic or thrombotic responses. They are mostly characterized by the presence of procoagulant phospholipids at their surface and eventually that of tissue factor depending on the cells they originate from. These procoagulant entities allow them to initiate and propagate thrombotic reactions within the blood vessels. MV are also recognized as proximal or remote mediators of cell-to-cell communication. The mechanisms through which MV interact with target cells remain unclear although a number of studies suggest involvement of MV-cell fusion and/or ligand-receptor interactions. It has however to be emphasized that MV do not necessarily elicit deleterious responses. This review focuses on the role of MV in cancer-associated thrombosis. (C) 2010 Elsevier Ltd. All rights reserved.